Zevra Therapeutics, Inc.
ZVRA
$12.24
-$0.44-3.43%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -76.90% | 211.47% | 2,336.21% | -100.73% | 2,510.68% |
| Total Depreciation and Amortization | -1.09% | 1.66% | -7.65% | -76.26% | 0.12% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 121.20% | -1,471.74% | -57.71% | 109.89% | -101,030.56% |
| Change in Net Operating Assets | -109.66% | 195.36% | -331.74% | 68.06% | -6.50% |
| Cash from Operations | 177.30% | 11.35% | 17.14% | 230.77% | 56.20% |
| Capital Expenditure | -520.00% | -212.90% | 105.60% | -160.09% | -115.15% |
| Sale of Property, Plant, and Equipment | -88.73% | 31,289.36% | -123.94% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -25.13% | 10,486.35% | 107.31% | -137.96% | 14.15% |
| Cash from Investing | -60.50% | 34,974.01% | 104.96% | -138.34% | 13.20% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -- | -- | -- | 100.00% |
| Issuance of Common Stock | -84.03% | 289.75% | -61.01% | 372.85% | -30.22% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 103.00% | -2,174.00% | -61.01% | 372.85% | -14.06% |
| Foreign Exchange rate Adjustments | -246.78% | 172.36% | -603.13% | -90.27% | 276.88% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 49.83% | 316.58% | 18.43% | -35.14% | 191.76% |